In this episode, Christopher Koddermann interviews Dr. Sam Banister: co-founder and chief scientific officer of Psylo, an Australian biotech company developing next-generation psychedelics. Banister discusses how he got involved in drug development, how Psylo came about, and the hallucinogenic and non-hallucinogenic 5-HT2A agonists Psylo is working on. He talks about the compromise between immediate need […]

The post PT491 – Drug Development, The State of Biotech, and Exploring Non-Hallucinogenic Compounds appeared first on Psychedelics Today.

Previous articlePα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls
Next articleProminent At-Home Ketamine Co. Founder, Juan Pablo Cappello, Sounds Alarm, Withdraws Support for the Practice